Selected research
Industry Growth & Trends
Global Cell and Gene Therapy Enterprise Solutions Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Cell and Gene Therapy Enterprise Solutions market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Cell and Gene Therapy Enterprise Solutions is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Cell and Gene Therapy Enterprise Solutions is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Cell and Gene Therapy Enterprise Solutions is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Cell and Gene Therapy Enterprise Solutions market include Thermo Fisher Scientific, Miltenyi Biotec, Bruker Spatial Biology, Charles River Laboratories, Sartorius, Revvity, Red Cross Blood Services, Proteintech Group and Promega Corporation, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Cell and Gene Therapy Enterprise Solutions market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Cell and Gene Therapy Enterprise Solutions market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Cell and Gene Therapy Enterprise Solutions market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Cell and Gene Therapy Enterprise Solutions.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Cell and Gene Therapy Enterprise Solutions market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Cell and Gene Therapy Enterprise Solutions Market by Company
Thermo Fisher Scientific
Miltenyi Biotec
Bruker Spatial Biology
Charles River Laboratories
Sartorius
Revvity
Red Cross Blood Services
Proteintech Group
Promega Corporation
BIOMÉRIEUX
QIAGEN
R&D Systems
Abcam
SGS
Azenta US
Vizient Inc
Cell and Gene Therapy Enterprise Solutions Segment by Type
Cell Therapy-Specific Solutions
Gene Therapy-Specific Solutions
Cell and Gene Therapy Enterprise Solutions Segment by Application
Academic/Research Lab
Biotech/Pharma Company
Clinical/Medical Institution
Cell and Gene Therapy Enterprise Solutions Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cell and Gene Therapy Enterprise Solutions market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cell and Gene Therapy Enterprise Solutions and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cell and Gene Therapy Enterprise Solutions.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Cell and Gene Therapy Enterprise Solutions companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Cell Therapy-Specific Solutions
- Gene Therapy-Specific Solutions
Applications
- Academic/Research Lab
- Biotech/Pharma Company
- Clinical/Medical Institution
Companies covered
- Thermo Fisher Scientific
- Miltenyi Biotec
- Bruker Spatial Biology
- Charles River Laboratories
- Sartorius
- Revvity
- Red Cross Blood Services
- Proteintech Group
- Promega Corporation
- BIOMÉRIEUX
- QIAGEN
- R&D Systems
- Abcam
- SGS
- Azenta US
- Vizient Inc
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Cell and Gene Therapy Enterprise Solutions Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Cell and Gene Therapy Enterprise Solutions Market Size by Region (2021-2032)
- 1.4.1 Global Cell and Gene Therapy Enterprise Solutions Market Size by Region (2021-2026)
- 1.4.2 Global Cell and Gene Therapy Enterprise Solutions Market Size by Region (2027-2032)
- 1.5 Key Regions Cell and Gene Therapy Enterprise Solutions Market Size (2021-2032)
- 1.5.1 North America Cell and Gene Therapy Enterprise Solutions Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Cell and Gene Therapy Enterprise Solutions Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Cell and Gene Therapy Enterprise Solutions Market Size Growth Rate (2021-2032)
- 1.5.4 South America Cell and Gene Therapy Enterprise Solutions Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Cell and Gene Therapy Enterprise Solutions Market Size Growth Rate (2021-2032)
2 Cell and Gene Therapy Enterprise Solutions Market by Type
- 2.1 Type Introduction
- 2.1.1 Cell Therapy-Specific Solutions
- 2.1.2 Gene Therapy-Specific Solutions
- 2.2 Global Cell and Gene Therapy Enterprise Solutions Market Size by Type
- 2.2.1 Global Cell and Gene Therapy Enterprise Solutions Market Size Overview by Type (2021-2032)
- 2.2.2 Global Cell and Gene Therapy Enterprise Solutions Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Cell and Gene Therapy Enterprise Solutions Market Size Forecasted by Type (2027-2032)
- 2.3 Global Cell and Gene Therapy Enterprise Solutions Market Size by Regions
- 2.3.1 North America Cell and Gene Therapy Enterprise Solutions Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Cell and Gene Therapy Enterprise Solutions Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Cell and Gene Therapy Enterprise Solutions Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Cell and Gene Therapy Enterprise Solutions Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Cell and Gene Therapy Enterprise Solutions Market Size Breakdown by Type (2021-2026)
3 Cell and Gene Therapy Enterprise Solutions Market by Application
- 3.1 Type Introduction
- 3.1.1 Academic/Research Lab
- 3.1.2 Biotech/Pharma Company
- 3.1.3 Clinical/Medical Institution
- 3.2 Global Cell and Gene Therapy Enterprise Solutions Market Size by Application
- 3.2.1 Global Cell and Gene Therapy Enterprise Solutions Market Size Overview by Application (2021-2032)
- 3.2.2 Global Cell and Gene Therapy Enterprise Solutions Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Cell and Gene Therapy Enterprise Solutions Market Size Forecasted by Application (2027-2032)
- 3.3 Global Cell and Gene Therapy Enterprise Solutions Market Size by Regions
- 3.3.1 North America Cell and Gene Therapy Enterprise Solutions Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Cell and Gene Therapy Enterprise Solutions Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Cell and Gene Therapy Enterprise Solutions Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Cell and Gene Therapy Enterprise Solutions Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Cell and Gene Therapy Enterprise Solutions Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Cell and Gene Therapy Enterprise Solutions Industry Trends
- 4.2 Cell and Gene Therapy Enterprise Solutions Industry Drivers
- 4.3 Cell and Gene Therapy Enterprise Solutions Industry Opportunities and Challenges
- 4.4 Cell and Gene Therapy Enterprise Solutions Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Cell and Gene Therapy Enterprise Solutions Revenue (2021-2026)
- 5.2 Global Cell and Gene Therapy Enterprise Solutions Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Cell and Gene Therapy Enterprise Solutions Key Company Headquarters & Area Served
- 5.4 Global Cell and Gene Therapy Enterprise Solutions Company, Product Type & Application
- 5.5 Global Cell and Gene Therapy Enterprise Solutions Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Cell and Gene Therapy Enterprise Solutions Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Cell and Gene Therapy Enterprise Solutions Players Market Share by Revenue in 2025
- 5.6.3 2025 Cell and Gene Therapy Enterprise Solutions Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Thermo Fisher Scientific
- 6.1.1 Thermo Fisher Scientific Company Information
- 6.1.2 Thermo Fisher Scientific Business Overview
- 6.1.3 Thermo Fisher Scientific Cell and Gene Therapy Enterprise Solutions Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Thermo Fisher Scientific Cell and Gene Therapy Enterprise Solutions Product Portfolio
- 6.1.5 Thermo Fisher Scientific Recent Developments
- 6.2 Miltenyi Biotec
- 6.2.1 Miltenyi Biotec Company Information
- 6.2.2 Miltenyi Biotec Business Overview
- 6.2.3 Miltenyi Biotec Cell and Gene Therapy Enterprise Solutions Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Miltenyi Biotec Cell and Gene Therapy Enterprise Solutions Product Portfolio
- 6.2.5 Miltenyi Biotec Recent Developments
- 6.3 Bruker Spatial Biology
- 6.3.1 Bruker Spatial Biology Company Information
- 6.3.2 Bruker Spatial Biology Business Overview
- 6.3.3 Bruker Spatial Biology Cell and Gene Therapy Enterprise Solutions Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Bruker Spatial Biology Cell and Gene Therapy Enterprise Solutions Product Portfolio
- 6.3.5 Bruker Spatial Biology Recent Developments
- 6.4 Charles River Laboratories
- 6.4.1 Charles River Laboratories Company Information
- 6.4.2 Charles River Laboratories Business Overview
- 6.4.3 Charles River Laboratories Cell and Gene Therapy Enterprise Solutions Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Charles River Laboratories Cell and Gene Therapy Enterprise Solutions Product Portfolio
- 6.4.5 Charles River Laboratories Recent Developments
- 6.5 Sartorius
- 6.5.1 Sartorius Company Information
- 6.5.2 Sartorius Business Overview
- 6.5.3 Sartorius Cell and Gene Therapy Enterprise Solutions Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Sartorius Cell and Gene Therapy Enterprise Solutions Product Portfolio
- 6.5.5 Sartorius Recent Developments
- 6.6 Revvity
- 6.6.1 Revvity Company Information
- 6.6.2 Revvity Business Overview
- 6.6.3 Revvity Cell and Gene Therapy Enterprise Solutions Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Revvity Cell and Gene Therapy Enterprise Solutions Product Portfolio
- 6.6.5 Revvity Recent Developments
- 6.7 Red Cross Blood Services
- 6.7.1 Red Cross Blood Services Company Information
- 6.7.2 Red Cross Blood Services Business Overview
- 6.7.3 Red Cross Blood Services Cell and Gene Therapy Enterprise Solutions Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Red Cross Blood Services Cell and Gene Therapy Enterprise Solutions Product Portfolio
- 6.7.5 Red Cross Blood Services Recent Developments
- 6.8 Proteintech Group
- 6.8.1 Proteintech Group Company Information
- 6.8.2 Proteintech Group Business Overview
- 6.8.3 Proteintech Group Cell and Gene Therapy Enterprise Solutions Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Proteintech Group Cell and Gene Therapy Enterprise Solutions Product Portfolio
- 6.8.5 Proteintech Group Recent Developments
- 6.9 Promega Corporation
- 6.9.1 Promega Corporation Company Information
- 6.9.2 Promega Corporation Business Overview
- 6.9.3 Promega Corporation Cell and Gene Therapy Enterprise Solutions Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Promega Corporation Cell and Gene Therapy Enterprise Solutions Product Portfolio
- 6.9.5 Promega Corporation Recent Developments
- 6.10 BIOMÉRIEUX
- 6.10.1 BIOMÉRIEUX Company Information
- 6.10.2 BIOMÉRIEUX Business Overview
- 6.10.3 BIOMÉRIEUX Cell and Gene Therapy Enterprise Solutions Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 BIOMÉRIEUX Cell and Gene Therapy Enterprise Solutions Product Portfolio
- 6.10.5 BIOMÉRIEUX Recent Developments
- 6.11 QIAGEN
- 6.11.1 QIAGEN Company Information
- 6.11.2 QIAGEN Business Overview
- 6.11.3 QIAGEN Cell and Gene Therapy Enterprise Solutions Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 QIAGEN Cell and Gene Therapy Enterprise Solutions Product Portfolio
- 6.11.5 QIAGEN Recent Developments
- 6.12 R&D Systems
- 6.12.1 R&D Systems Company Information
- 6.12.2 R&D Systems Business Overview
- 6.12.3 R&D Systems Cell and Gene Therapy Enterprise Solutions Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 R&D Systems Cell and Gene Therapy Enterprise Solutions Product Portfolio
- 6.12.5 R&D Systems Recent Developments
- 6.13 Abcam
- 6.13.1 Abcam Company Information
- 6.13.2 Abcam Business Overview
- 6.13.3 Abcam Cell and Gene Therapy Enterprise Solutions Revenue, Global Share and Gross Margin (2021-2026)
- 6.13.4 Abcam Cell and Gene Therapy Enterprise Solutions Product Portfolio
- 6.13.5 Abcam Recent Developments
- 6.14 SGS
- 6.14.1 SGS Company Information
- 6.14.2 SGS Business Overview
- 6.14.3 SGS Cell and Gene Therapy Enterprise Solutions Revenue, Global Share and Gross Margin (2021-2026)
- 6.14.4 SGS Cell and Gene Therapy Enterprise Solutions Product Portfolio
- 6.14.5 SGS Recent Developments
- 6.15 Azenta US
- 6.15.1 Azenta US Company Information
- 6.15.2 Azenta US Business Overview
- 6.15.3 Azenta US Cell and Gene Therapy Enterprise Solutions Revenue, Global Share and Gross Margin (2021-2026)
- 6.15.4 Azenta US Cell and Gene Therapy Enterprise Solutions Product Portfolio
- 6.15.5 Azenta US Recent Developments
- 6.16 Vizient Inc
- 6.16.1 Vizient Inc Company Information
- 6.16.2 Vizient Inc Business Overview
- 6.16.3 Vizient Inc Cell and Gene Therapy Enterprise Solutions Revenue, Global Share and Gross Margin (2021-2026)
- 6.16.4 Vizient Inc Cell and Gene Therapy Enterprise Solutions Product Portfolio
- 6.16.5 Vizient Inc Recent Developments
7 North America
- 7.1 North America Cell and Gene Therapy Enterprise Solutions Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Cell and Gene Therapy Enterprise Solutions Market Size by Country (2021-2026)
- 7.3 North America Cell and Gene Therapy Enterprise Solutions Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Cell and Gene Therapy Enterprise Solutions Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Cell and Gene Therapy Enterprise Solutions Market Size by Country (2021-2026)
- 8.3 Europe Cell and Gene Therapy Enterprise Solutions Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Cell and Gene Therapy Enterprise Solutions Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Cell and Gene Therapy Enterprise Solutions Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Cell and Gene Therapy Enterprise Solutions Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Cell and Gene Therapy Enterprise Solutions Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Cell and Gene Therapy Enterprise Solutions Market Size by Country (2021-2026)
- 10.3 South America Cell and Gene Therapy Enterprise Solutions Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Cell and Gene Therapy Enterprise Solutions Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Cell and Gene Therapy Enterprise Solutions Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Cell and Gene Therapy Enterprise Solutions Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst